Zymeworks Inc. (ZYME) Stock Grade

About Zymeworks Inc.'s fundamentals

Zymeworks is a biotechnology company with a market capitalization of $2.0 billion that is experiencing strong revenue growth of 38.9% year-over-year, indicating expanding business activity. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -76.6%, meaning it is spending significantly more than it generates in revenue. The company does not pay a dividend, which is typical for early-stage biotech firms that reinvest losses into research and development. Given the absence of profitability metrics, traditional valuation measures like P/E ratio and return on equity are not applicable.